Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Screeners that run automatically... and then email you the results! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Leap Therapeutics Inc (LPTX)
Leap Therapeutics Inc (LPTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 101,129
  • Shares Outstanding, K 119,411
  • Annual Sales, $ 0 K
  • Annual Income, $ -54,600 K
  • 60-Month Beta 0.67
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.93
Trade LPTX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.71
  • Most Recent Earnings -0.32 on 05/15/23
  • Next Earnings Date 05/12/23
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 222.07% ( +27.91%)
  • Historical Volatility 127.62%
  • IV Percentile 60%
  • IV Rank 15.18%
  • IV High 1,452.08% on 12/15/22
  • IV Low 1.99% on 06/15/22
  • Put/Call Vol Ratio 0.87
  • Today's Volume 133
  • Volume Avg (30-Day) 374
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 5,286
  • Open Int (30-Day) 3,136

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/23
See More
  • Average Estimate -0.10
  • Number of Estimates 3
  • High Estimate -0.09
  • Low Estimate -0.11
  • Prior Year -0.15
  • Growth Rate Est. (year over year) +33.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3810 +88.98%
on 05/08/23
1.0200 -29.41%
on 06/01/23
+0.3311 (+85.14%)
since 05/05/23
3-Month
0.2700 +166.67%
on 03/27/23
1.0200 -29.41%
on 06/01/23
+0.1781 (+32.87%)
since 03/06/23
52-Week
0.2700 +166.67%
on 03/27/23
1.8600 -61.29%
on 09/08/22
-0.3700 (-33.94%)
since 06/06/22

Most Recent Stories

More News
Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting

/PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today...

LPTX : 0.7088 (-16.61%)
Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting

/PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today...

LPTX : 0.7088 (-16.61%)
Leap Therapeutics Announces Completion of Enrollment in Part A of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients

/PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced...

LPTX : 0.7088 (-16.61%)
Leap Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

/PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported...

LPTX : 0.7088 (-16.61%)
Leap Therapeutics Provides Update on BeiGene Option Agreement for DKN-01

/PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced...

LPTX : 0.7088 (-16.61%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CNCE, AQUA, LPTX, ALR

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

CNCE : 8.37 (+0.12%)
AQUA : 49.88 (+0.95%)
LPTX : 0.7088 (-16.61%)
ALR : 1.3200 (+0.76%)
SHAREHOLDER ALERT: Weiss Law Reminds AQUA, LPTX, CNCE, and ALBO Shareholders About Its Ongoing Investigations

/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...

AQUA : 49.88 (+0.95%)
LPTX : 0.7088 (-16.61%)
CNCE : 8.37 (+0.12%)
ALBO : 44.15 (-0.23%)
Moore Kuehn Encourages ALR, CEMI, LPTX, and ATCX Investors to Contact Law Firm

/PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential...

ALR : 1.3200 (+0.76%)
CEMI : 0.4550 (+0.22%)
LPTX : 0.7088 (-16.61%)
ATCX : 12.25 (+0.66%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALBO, CNCE, AQUA, LPTX

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

ALBO : 44.15 (-0.23%)
CNCE : 8.37 (+0.12%)
AQUA : 49.88 (+0.95%)
LPTX : 0.7088 (-16.61%)
SHAREHOLDER ALERT: Weiss Law Reminds AQUA, LPTX, CNCE, and ALBO Shareholders About Its Ongoing Investigations

/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...

AQUA : 49.88 (+0.95%)
LPTX : 0.7088 (-16.61%)
CNCE : 8.37 (+0.12%)
ALBO : 44.15 (-0.23%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Leap Therapeutics, Inc. is a biopharmaceutical company. It develops novel therapeutics for the treatment of cancer. Leap Therapeutics, Inc. is based in Cambridge, United States.

See More

Key Turning Points

3rd Resistance Point 0.9506
2nd Resistance Point 0.9153
1st Resistance Point 0.8811
Last Price 0.7088
1st Support Level 0.8116
2nd Support Level 0.7763
3rd Support Level 0.7421

See More

52-Week High 1.8600
Fibonacci 61.8% 1.2526
Fibonacci 50% 1.0650
Fibonacci 38.2% 0.8774
Last Price 0.7088
52-Week Low 0.2700

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar